Sarepta Therapeutics (SRPT) Cash from Financing Activities (2010 - 2026)

Sarepta Therapeutics has reported Cash from Financing Activities for 17 years, with the latest figure at $241000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 98.07% year-over-year to $241000.0; the trailing twelve-month figure through Mar 2026 stood at -$180.6 million (down 256.83% YoY), and the FY2025 full-year result was -$168.3 million, down 234.88% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $241000.0, up from -$39.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $216.4 million in Q3 2022, with the low at -$117.8 million in Q3 2025.
• Average Cash from Financing Activities over 5 years is $18.5 million, with a median of $10.7 million recorded in 2022.
• Year-over-year, Cash from Financing Activities soared 3567.05% in 2022 and plunged 956.22% in 2025.
• Tracing SRPT's Cash from Financing Activities over 5 years: stood at $10.7 million in 2022, then tumbled by 81.92% to $1.9 million in 2023, then jumped by 2421.41% to $49.0 million in 2024, then slumped by 180.03% to -$39.2 million in 2025, then jumped by 100.61% to $241000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $241000.0 (Q1 2026), -$39.2 million (Q4 2025), and -$117.8 million (Q3 2025), per Business Quant data.

Peer Comparison